Table 2 EQ-5D-3 L index score by target joint status
From: The impact of severe haemophilia and the presence of target joints on health-related quality-of-life
Total (n = 515) | No target joints (n = 157) | ≥1 target joints (n = 358) | |
|---|---|---|---|
Total | 0.77 ± 0.27 | 0.87 ± 0.01 | 0.73 ± 0.29 |
Age categories | |||
18–30 | 0.86 ± 0.01 | 0.94 ± 0.01 | 0.82 ± 0.21 |
31–40 | 0.78 ± 0.23 | 0.84 ± 0.16 | 0.74 ± 0.25 |
41–50 | 0.72 ± 0.28 | 0.86 ± 0.12 | 0.69 ± 0.30 |
51–60 | 0.67 ± 0.34 | 0.83 ± 0.19 | 0.63 ± 0.36 |
61 + | 0.61 ± 0.36 | 0.73 ± 0.31 | 0.54 ± 0.36 |
Subtype | |||
Haemophilia A | 0.78 ± 0.26 | 0.87 ± 0.18 | 0.74 ± 0.28 |
Haemophilia B | 0.76 ± 0.29 | 0.86 ± 0.18 | 0.70 ± 0.32 |
Country | |||
France | 0.75 ± 0.28 | 0.87 ± 0.18 | 0.69 ± 0.30 |
Germany | 0.90 ± 0.12 | 0.93 ± 0.09 | 0.88 ± 0.13 |
Italy | 0.85 ± 0.12 | 0.86 ± 0.14 | 0.84 ± 0.11 |
Spain | 0.66 ± 0.34 | 0.71 ± 0.36 | 0.65 ± 0.33 |
UK | 0.59 ± 0.36 | 0.78 ± 0.17 | 0.56 ± 0.38 |
Treatment strategy | |||
On-demand | 0.80 ± 0.26 | 0.87 ± 0.21 | 0.77 ± 0.27 |
Prophylaxis | 0.75 ± 0.01 | 0.87 ± 0.01 | 0.71 ± 0.29 |
Physician reported comorbidities | |||
Depression | 0.60 ± 0.36 | 0.79 ± 0.33 | 0.55 ± 0.35 |
Anxiety | 0.80 ± 0.26 | 0.87 ± 0.21 | 0.77 ± 0.27 |
Number of target joints (patient n, %) | |||
One | – | – | 0.76 ± 0.28 |
Two | – | – | 0.76 ± 0.26 |
Three or more | – | – | 0.62 ± 0.31 |
Location of target joints (patient n, %) | |||
Exclusively upper body | – | – | 0.77 ± 0.27 |
Exclusively lower body | – | – | 0.73 ± 0.28 |
Upper and lower body | – | – | 0.68 ± 0.31 |